Siegel, R. L., Miller, Ok. D., Wagle, N. S. & Jemal, A. Most cancers statistics, 2023. Ca Most cancers J. Clin. 73, 17–48 (2023).
Sartor, O. & de Bono, J. S. Metastatic prostate most cancers. N. Engl. J. Med. 378, 1653–1654 (2018).
Sandhu, S. et al. Prostate most cancers. Lancet 398, 1075–1090 (2021).
Beltran, H. et al. The position of lineage plasticity in prostate most cancers remedy resistance. Clin. Most cancers Res. 25, 6916–6924 (2019).
Labrecque, M. P. et al. Molecular profiling stratifies various phenotypes of treatment-refractory metastatic castration-resistant prostate most cancers. J. Clin. Make investments 129, 4492–4505 (2019).
Bluemn, E. G. et al. Androgen receptor pathway-independent prostate most cancers is sustained via FGF signaling. Most cancers Cell 32, 474–489.e6 (2017).
Haffner, M. C. et al. Genomic and phenotypic heterogeneity in prostate most cancers. Nat. Rev. Urol. 18, 79–92 (2021).
Davies, A., Conteduca, V., Zoubeidi, A. & Beltran, H. Organic evolution of castration-resistant prostate most cancers. Eur. Urol. Focus 5, 147–154 (2019).
Kulac, I., Roudier, M. P. & Haffner, M. C. Molecular pathology of prostate most cancers. Surg. Pathol. Clin. 14, 387–401 (2021).
Beltran, H. & Demichelis, F. Remedy concerns in neuroendocrine prostate most cancers: what subsequent? Endocr.-relat. Most cancers 28, T67–T78 (2021).
Davies, A. H., Beltran, H. & Zoubeidi, A. Mobile plasticity and the neuroendocrine phenotype in prostate most cancers. Nat. Rev. Urol. 15, 271–286 (2018).
Weber, E. W., Maus, M. V. & Mackall, C. L. The rising panorama of immune cell therapies. Cell 181, 46–62 (2020).
Hu, Z. et al. The most cancers surfaceome atlas integrates genomic, useful and drug response knowledge to determine actionable targets. Nat. Most cancers 2, 1406–1422 (2021).
Carter, P. J. & Lazar, G. A. Subsequent technology antibody medicine: pursuit of the “high-hanging fruit. Nat. Rev. Drug Discov. 17, 197–223 (2018).
Rosellini, M. et al. Treating prostate most cancers by antibody–drug conjugates. Int J. Mol. Sci. 22, 1551 (2021).
Drago, J. Z., Modi, S. & Chandarlapaty, S. Unlocking the potential of antibody–drug conjugates for most cancers remedy. Nat. Rev. Clin. Oncol. 18, 327–344 (2021).
Fu, Z., Li, S., Han, S., Shi, C. & Zhang, Y. Antibody drug conjugate: the “organic missile” for focused most cancers remedy. Sign Transduct. Goal Ther. 7, 93 (2022).
Sheehan, B. et al. Prostate-specific membrane antigen biology in deadly prostate most cancers and its therapeutic implications. Eur. Urol. Focus 8, 1157–1168 (2022).
Miyahira, A. Ok. et al. Assembly report from the Prostate Most cancers Basis PSMA Theranostics State of the Science assembly. Prostate 80, 1273–1296 (2020).
Sayar, E. et al. Reversible epigenetic alterations mediate PSMA expression heterogeneity in superior metastatic prostate most cancers. JCI Perception. https://doi.org/10.1172/jci.perception.162907 (2023).
Bakht, M. Ok. et al. Panorama of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate most cancers. Nat. Most cancers 4, 699–715 (2023).
Paschalis, A. et al. Prostate-specific membrane antigen heterogeneity and DNA restore defects in prostate most cancers. Eur. Urol. 76, 469–478 (2019).
Giffin, M. J. et al. AMG 757, a half-life prolonged, DLL3-targeted bispecific T-cell engager, exhibits excessive efficiency and sensitivity in preclinical fashions of small-cell lung most cancers. Clin. Most cancers Res. 27, 1526–1537 (2021).
Yao, J. et al. DLL3 as an rising goal for the remedy of neuroendocrine neoplasms. Oncology 27, 940–951 (2022).
Puca, L. et al. Delta-like protein 3 expression and therapeutic focusing on in neuroendocrine prostate most cancers. Sci. Transl. Med. 11, eaav0891 (2019).
DeLucia, D. C. et al. Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5–SN38 antibody–drug conjugate in neuroendocrine prostate most cancers. Clin. Most cancers Res. 27, 759–774 (2021).
Sperger, J. M. et al. Expression and therapeutic focusing on of Trop-2 in remedy resistant prostate most cancers. Clin. Most cancers Res. Official J. Am. Assoc. Most cancers Res. 29, 2324–2335 (2022).
Sardinha, M. Sr. et al. Antibody-drug conjugates in prostate most cancers: a scientific assessment. Cureus J. Med. Sci. 15, e34490 (2023).
Mansfield, A. S. et al. A section I/II examine of rovalpituzumab tesirine in delta-like 3—expressing superior stable tumors. Npj Summary Oncol. 5, 74 (2021).
Lee, J. Ok. et al. Systemic surfaceome profiling identifies goal antigens for immune-based remedy in subtypes of superior prostate most cancers. Proc. Natl Acad. Sci. USA 115, E4473–E4482 (2018).
Decary, S. et al. Preclinical exercise of SAR408701: a novel anti-CEACAM5–maytansinoid antibody–drug conjugate for the remedy of CEACAM5-positive epithelial tumors. Clin. Most cancers Res. 26, 6589–6599 (2020).
Gazzah, A. et al. Security, pharmacokinetics, and antitumor exercise of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in sufferers with superior stable tumors: first-in-human dose-escalation examine. Ann. Oncol. 33, 416–425 (2022).
Lipinski, M., Parks, D. R., Rouse, R. V. & Herzenberg, L. A. Human trophoblast cell-surface antigens outlined by monoclonal antibodies. Proc. Natl Acad. Sci. USA 78, 5147–5150 (1981).
Cardillo, T. M., Govindan, S. V., Sharkey, R. M., Trisal, P. & Goldenberg, D. M. Humanized anti-trop-2 IgG-SN-38 conjugate for efficient remedy of various epithelial cancers: preclinical research in human most cancers xenograft fashions and monkeys. Clin. Most cancers Res. 17, 3157–3169 (2011).
Bardia, A. et al. Sacituzumab govitecan in metastatic triple-negative breast most cancers. N. Engl. J. Med 384, 1529–1541 (2021).
Tagawa, S. T. et al. TROPHY-U-01: a section II open-label examine of sacituzumab govitecan in sufferers with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J. Clin. Oncol. 39, 2474–2485 (2021).
Patel, R. A. et al. Complete evaluation of anaplastic lymphoma kinase in localized and metastatic prostate most cancers reveals targetable alterationsALK alterations in prostate most cancers. Most cancers Res. Commun. 2, 277–285 (2022).
Kumar, A. et al. Substantial interindividual and restricted intraindividual genomic range amongst tumors from males with metastatic prostate most cancers. Nat. Med. 22, 369–378 (2016).
Sartor, O. et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate most cancers. N. Engl. J. Med. 385, 1091–1103 (2021).
Hofman, M. S. et al. 177Lu]Lu-PSMA-617 versus cabazitaxel in sufferers with metastatic castration-resistant prostate most cancers (TheraP): a randomised, open-label, section 2 trial. Lancet 397, 797–804 (2021).
Buteau, J. P. et al. PSMA and FDG-PET as predictive and prognostic biomarkers in sufferers given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate most cancers (TheraP): a biomarker evaluation from a randomised, open-label, section 2 trial. Lancet Oncol. 23, 1389–1397 (2022).
Sheehan, B. et al. Prostate particular membrane antigen expression and response to DNA damaging brokers in prostate most cancers. Clin. Most cancers Res. 28, 3104–3115 (2022).
Shastry, M., Jacob, S., Rugo, H. S. & Hamilton, E. Antibody-drug conjugates focusing on TROP-2: medical improvement in metastatic breast most cancers. Breast 66, 169–177 (2022).
Hsu, E.-C. et al. Trop2 is a driver of metastatic prostate most cancers with neuroendocrine phenotype through PARP1. Proc. Natl Acad. Sci. USA 117, 2032–2042 (2020).
Chou, J. et al. Immunotherapeutic focusing on and PET imaging of DLL3 in small-cell neuroendocrine prostate most cancers. Most cancers Res. 83, 301–315 (2022).
Hipp, S. et al. A bispecific DLL3/CD3 IgG-Like T-cell participating antibody induces antitumor responses in small cell lung most cancers. Clin. Most cancers Res. 26, 5258–5268 (2020).
Ku, S.-Y., Yamada, Y., Ng, P., Solar, L. & Beltran, H. Summary 2896: DLL3-targeted T cell engager remedy (HPN328) for neuroendocrine prostate most cancers. Most cancers Res. 82, 2896–2896 (2022).
Johnson, M. L. et al. Interim outcomes of an ongoing section 1/2a examine of HPN328, a tri-specific, half-life prolonged, DLL3-targeting, T-cell engager, in sufferers with small cell lung most cancers and different neuroendocrine cancers. J. Clin. Oncol. 40, 8566–8566 (2022).
Mu, P. et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate most cancers. Science 355, 84–88 (2017).
Nyquist, M. D. et al. Mixed TP53 and RB1 loss promotes prostate most cancers resistance to a spectrum of therapeutics and confers vulnerability to replication stress. Cell Rep. 31, 107669 (2020).
Sarkar, N. D. et al. Genomic attributes of homology-directed DNA restore deficiency in metastatic prostate most cancers. JCI Perception 6, e152789 (2021).
Zhou, M. et al. Patterns of structural variation outline prostate most cancers throughout illness states. JCI Perception 7, e161370 (2022).
Quigley, D. A. et al. Genomic hallmarks and structural variation in metastatic prostate most cancers. Cell 174, 758–769.e9 (2018).
Baca, S. C. et al. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate most cancers. Nat. Commun. 12, 1979 (2021).
Patel, R. A. et al. Characterization of HOXB13 expression patterns in localized and metastatic castration‐resistant prostate most cancers. J. Pathol. 262, 105–120 (2023).
Zhao, S. G. et al. The DNA methylation panorama of superior prostate most cancers. Nat. Genet. 52, 778–789 (2020).
Cejas, P. et al. Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate most cancers. Nat. Commun. 12, 5775 (2021).
Pomerantz, M. M. et al. Prostate most cancers reactivates developmental epigenomic packages throughout metastatic development. Nat. Genet 52, 790–799 (2020).
Cibulskis, Ok. et al. Delicate detection of somatic level mutations in impure and heterogeneous most cancers samples. Nat. Biotechnol. 31, 213–219 (2013).
Kim, S. et al. Strelka2: quick and correct calling of germline and somatic variants. Nat. Strategies 15, 591–594 (2018).
Koboldt, D. C. et al. VarScan 2: Somatic mutation and replica quantity alteration discovery in most cancers by exome sequencing. Genome Res. 22, 568–576 (2012).
Wala, J. A. et al. SvABA: genome-wide detection of structural variants and indels by native meeting. Genome Res. 28, 581–591 (2018).
Wang, Ok., Li, M. & Hakonarson, H. ANNOVAR: useful annotation of genetic variants from high-throughput sequencing knowledge. Nucleic Acids Res. 38, e164–e164 (2010).
Ha, G. et al. TITAN: inference of copy quantity architectures in clonal cell populations from tumor whole-genome sequence knowledge. Genome Res. 24, 1881–1893 (2014).
